WO2016059507A1 - Improved process for the preparation of high pure metformine - Google Patents
Improved process for the preparation of high pure metformine Download PDFInfo
- Publication number
- WO2016059507A1 WO2016059507A1 PCT/IB2015/057575 IB2015057575W WO2016059507A1 WO 2016059507 A1 WO2016059507 A1 WO 2016059507A1 IB 2015057575 W IB2015057575 W IB 2015057575W WO 2016059507 A1 WO2016059507 A1 WO 2016059507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metformin hydrochloride
- preparation
- process according
- metformin
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
Definitions
- the present invention relates to an improved process for the preparation of Metformin compound of formula-I or its pharmaceutically acceptable salts thereof.
- Metformin hydrochloride is described chemically as N,N- Dimethylimidodicarbonimidic diamide hydrochloride (CAS# 1115-70-4).
- the empirical formula of Metformin hydrochloride is C 4 H 11 N 5 .HCI and its molecular weight is 165.62 g/mol.
- the molecular structure of Metformin hydrochloride is represented by Formula I.
- Metformin also known by other name like 1,1-dimethylbiguanide, it is first described in the scientific literature in J. Chem, Soc, 1922, 121, 1790. It is the only one available biguanide, most widely prescribed orally administered antidiabetic drug for the treatment of type 2-diabetes. It is also used for the treatment of polycystic ovary syndrome
- Metformin hydrochloride The advantages of Metformin hydrochloride are a very low risk of hypoglycaemia, weight neutrality and reduced risk of cardiovascular morbidity and mortality.
- US patent no. 2,448,448 discloses use of 1, 1-dimethylbiguanide in dyeing of textile fibers, wherein 1,1-dimetylbiguanide is prepared by reacting dicyandiamide with dimethylamine.
- US patent no 3 174,901 discloses composition containing 1,1- dimethylbiguanide in the form of hydrochloride salt used for treating diabetes by oral administration.
- FR patent no 2322860 discloses preparation of Metformin hydrochloride by reacting equimolar amounts of dimethylamine and dicyandiamide in xylene followed by treating with HC1 gas to obtain crude Metformin hydrochloride is further purified by methanol.
- CN patent no 100391939 discloses a preparation of Metformin hydrochloride by treating 40% aqueous dimethylamine solution with 31% hydrochloric acid followed by dicyandiamide in ethanol to get crude compound, followed by recrystallization with ethanol to obtain Metformin hydrochloride with 75-80 % yield.
- the main object of the present invention is to provide an improved process for the preparation of highly pure Metformin hydrochloride compound of Formula I.
- Another object of the present invention is use of single organic solvent for the preparation of highly pure Metformin hydrochloride compound of Formula I.
- Yet another object of the present invention is use of single alcoholic solvent for the preparation of pure Metformin hydrochloride compound of Formula I.
- Yet another object of the present invention is use of n-butanol (is also a food grade material use in the industries) alcoholic solvent for the preparation of pure Metformin hydrochloride compound of Formula I.
- the present invention provides an improved process for the preparation of Metformin hydrochloride compound of formula I, which comprises the steps of
- alcohol includes primary, secondary and tertiary alcohols, preferably primary alcohols; more preferably n-butanol.
- the second aspect of invention is use of 0.4 to 4.0 kg of n-butanol for 1 kg of 2- cyanoguanidine.
- preparation of Metformin hydrochloride having purity > 99.9 % In the fourth aspect of the invention is preparation of high yield of Metformin hydrochloride is about >92 to 98 %.
- n-butanol which is also a food grade material use in the industries, will minimize the multiple residual solvents and improves the quality and purity of the API which leads to consumption of finished formulations at patient end for safe use.
- Figure: 1 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example- 1.
- Figure: 2 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example-2.
- Figure: 3 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example-3.
- the present invention provides an improved process for the preparation of highly pure metformin hydrochloride crystal by using single alcoholic solvent.
- the simple process offers high yield and low level of impurities makes the process more convenient and economical, particularly on commercial scale.
- the invention provides a process for preparation of Metformin hydrochloride, which comprises the steps of:
- step (iii) With or without washing step (ii) with alcoholic solvent and drying to get compound of formula- 1 as a pure product.
- 2-cyanoguanidine and dimethyl amine hydrochloride were added to alcoholic solvent to form the reaction mixture.
- the reaction mixture is condensed using the cooling water condenser for 16-28 hr.
- the resulting reaction mass is cooled to ambient temperature, preferably 10-110°C.
- the reaction mass is filtered to receive the wet mass.
- the wet mass can be washed with n-butanol and dried to get pure Metformin hydrochloride.
- the reaction mass is filtered and dried using standard techniques that have been widely used in industry.
- the alcohols that are selected include primary, secondary and tertiary alcohols, preferably primary alcohols; more preferably n-butanol.
- the Metformin hydrochloride prepared by this method have purity >99.9%.
- Impurity -F is Dimethylaniine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention provided an improved process for the preparation of Metformin compound of formula I or its pharmaceutically acceptable salts 5 thereof, by employing an alcoholic solvent throughout the process
Description
FIELD OF INVENTION
The present invention relates to an improved process for the preparation of Metformin compound of formula-I or its pharmaceutically acceptable salts thereof.
BACKGROUND OF THE INVENTION
Metformin hydrochloride is described chemically as N,N- Dimethylimidodicarbonimidic diamide hydrochloride (CAS# 1115-70-4). The empirical formula of Metformin hydrochloride is C4H11N5.HCI and its molecular weight is 165.62 g/mol. The molecular structure of Metformin hydrochloride is represented by Formula I.
Formula I
Metformin, also known by other name like 1,1-dimethylbiguanide, it is first described in the scientific literature in J. Chem, Soc, 1922, 121, 1790. It is the only one available biguanide, most widely prescribed orally administered antidiabetic drug for the treatment of type 2-diabetes. It is also used for the treatment of polycystic ovary syndrome
The advantages of Metformin hydrochloride are a very low risk of hypoglycaemia, weight neutrality and reduced risk of cardiovascular morbidity and mortality.
In US patent no. 2,448,448 discloses use of 1, 1-dimethylbiguanide in dyeing of textile fibers, wherein 1,1-dimetylbiguanide is prepared by reacting dicyandiamide with dimethylamine. In US patent no 3, 174,901 discloses composition containing 1,1- dimethylbiguanide in the form of hydrochloride salt used for treating diabetes by oral administration.
In DE patent no. 1023757 discloses preparation of Metformin hydrochloride by reacting dicyandiamide with dimethylamine hydrochloride in xylene at reflux temperature and crystallization with water to obtain Metformin hydrochloride with 47% yield.
In FR patent no 2322860 discloses preparation of Metformin hydrochloride by reacting equimolar amounts of dimethylamine and dicyandiamide in xylene followed by treating with HC1 gas to obtain crude Metformin hydrochloride is further purified by methanol.
In US patent application no 2011/021634 discloses preparation of Metformin hydrochloride substantially free from dimethylamine wherein an aqueous solution of Metformin hydrochloride is concentrated to remove water and the obtained residue is treated with C1-C4 alcohols to obtain pure Metformin hydrochloride.
In an Indian patent 189077 discloses a preparation of Metformin hydrochloride in absence of solvents followed by purification to obtain pure Metformin hydrochloride crystals.
In CN patent no 100391939 discloses a preparation of Metformin hydrochloride by treating 40% aqueous dimethylamine solution with 31% hydrochloric acid followed by dicyandiamide in ethanol to get crude compound, followed by
recrystallization with ethanol to obtain Metformin hydrochloride with 75-80 % yield.
In IN patent application No. 1350/MUM/2007 discloses preparation of highly pure Metformin hydrochloride substantially free from melamine and cyanoguanidine impurities by condensation of dimethylamine hydrochloride with dicyandiamide in xylene; extracting the product into water followed by distillation of water under vacuum at 65-72°C and crystallizing Metformin hydrochloride from methanol or a mixture of water and methanol.
In IN patent application No. 1346/MUM/2008 discloses a one-pot process for preparation of highly pure Metformin hydrochloride substantially free from melamine and cyanoguanidine impurities by reacting dimethylamine hydrochloride solution prepared insitu with cyanoguanidine in xylene, extracting metformin hydrochloride in to water, and distillation of around 50% of water followed by isolation.
In PCT publication no. 2010146604 discloses a preparation of Metformin hydrochloride using hydrocarbon solvents, followed by treating with water and alcoholic solvents to get Metformin hydrochloride as a product.
In PCT publication no. 2014041566 discloses a preparation of Metformin hydrochloride by removing solvents from the Metformin hydrochloride solution using agitated thin film dryer technique.
In Pharmaceutical Chemistry Journal, 1987, 21 (12), 892-894 discloses a preparation of Metformin hydrochloride by using n-butanol, followed by purification with isopropanol to obtain Metformin Hydrochloride as a final product with 65% yield.
Above mentioned prior art processes for the preparation of Metformin hydrochloride suffers from several disadvantages like decrease in yield of final compound, difficult in removal of the solvents during process, formation of several impurities during process, which are not economic at commercial scale. Further prior art processes involves non food grade solvent which will impact the final compound.
Substantially these factors affect the commercial viability of manufacturing process of Metformin hydrochloride. Therefore, there is a need to develop an improved process for the preparation of Metformin hydrochloride which can be practiced on large scale to produce Metformin hydrochloride in a cost efficient manner.
OBJECTIVE OF THE INVENTION
The main object of the present invention is to provide an improved process for the preparation of highly pure Metformin hydrochloride compound of Formula I.
Another object of the present invention is use of single organic solvent for the preparation of highly pure Metformin hydrochloride compound of Formula I.
Yet another object of the present invention is use of single alcoholic solvent for the preparation of pure Metformin hydrochloride compound of Formula I. Yet another object of the present invention is use of n-butanol (is also a food grade material use in the industries) alcoholic solvent for the preparation of pure Metformin hydrochloride compound of Formula I.
SUMMARY OF THE INVENTION
In an embodiment, the present invention provides an improved process for the preparation of Metformin hydrochloride compound of formula I, which comprises the steps of
i) treating dimethyl amine in the form of hydrochloride (DMA HCI) with 2- cyanoguanidine (DCDA) in presence of alcoholic solvent at ambient to reflux temperature.
ii) isolation of Metformin by filtration.
iii) With or without washing step (ii) with alcoholic solvent and drying to get compound of formula- 1 as a pure product.
According to present invention the term alcohol includes primary, secondary and tertiary alcohols, preferably primary alcohols; more preferably n-butanol.
In the first aspect of invention is use of minimum amount of n-butanol for the preparation of Metformin Hydrochloride.
In the second aspect of invention is use of 0.4 to 4.0 kg of n-butanol for 1 kg of 2- cyanoguanidine. In the third aspect of invention is preparation of Metformin hydrochloride having purity > 99.9 %
In the fourth aspect of the invention is preparation of high yield of Metformin hydrochloride is about >92 to 98 %.
In the fifth aspect of invention is preparation of highly pure Metformin hydrochloride, with residual quantity of Dimethyl amine is less than 5 ppm.
Unlike prior art the present invention involves the use of n-butanol , which is also a food grade material use in the industries, will minimize the multiple residual solvents and improves the quality and purity of the API which leads to consumption of finished formulations at patient end for safe use.
BRIEF DESCRIPTION OF DRAWINGS
Figure: 1 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example- 1.
Figure: 2 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example-2. Figure: 3 depicts X-ray diffraction pattern of crystalline Metformin hydrochloride as per example-3.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides an improved process for the preparation of highly pure metformin hydrochloride crystal by using single alcoholic solvent. The simple process offers high yield and low level of impurities makes the process more convenient and economical, particularly on commercial scale.
In an embodiment, the invention provides a process for preparation of Metformin hydrochloride, which comprises the steps of:
i) treating dimethyl amine in the form of hydrochloride (DMA HC1) with 2- cyanoguanidine (DCDA) in presence of alcoholic solvent at ambient to reflux temperature.
ii) isolation of Metformin by filtration.
iii) With or without washing step (ii) with alcoholic solvent and drying to get compound of formula- 1 as a pure product. 2-cyanoguanidine and dimethyl amine hydrochloride were added to alcoholic solvent to form the reaction mixture. The reaction mixture is condensed using the cooling water condenser for 16-28 hr. The resulting reaction mass is cooled to ambient temperature, preferably 10-110°C. The reaction mass is filtered to receive the wet mass. The wet mass can be washed with n-butanol and dried to get pure Metformin hydrochloride. The reaction mass is filtered and dried using standard techniques that have been widely used in industry.
The alcohols that are selected include primary, secondary and tertiary alcohols, preferably primary alcohols; more preferably n-butanol.
According to another aspect of invention, the Metformin hydrochloride prepared by this method have purity >99.9%.
In another aspect of the invention is preparation of high yield of Metformin hydrochloride is about >92 to 98%.
In yet another aspect of invention is preparation of highly pure Metformin hydrochloride, with residual quantity of Dimethyl amine is less than 5 ppm. The final product has low level of other impurities wherein melamine and 2- cyanoguanidine (DCDA) is less than 0.02%, more preferably 0.01%.
EXAMPLES
In the following examples, the preferred embodiment of the present invention is described only by way of illustrating the processes of the invention. However, these are not intended to limit the scope of the invention in any way.
Example: 1 Preparation of Metformin hydrochloride (Formula 1)
84.07 g of 2-cyanoguanidine and 81.54 g of Dimethyl amine hydrochloride were added to 100 g of n-butanol in a 500 mL glass flask. The flask was equipped with cooling water condenser and the flask was allowed to reflux for 16 h The resulting reaction mass was cooled to ambient temperature, preferably 10-110°C and filtered. The obtained wet solid was washed with 50g of n-butanol and dried to get Pure Metformin hydrochloride (160g).
EXAMPLE 2: Preparation of Metformin hydrochloride (Formula 1)
100 g of 2-cyanoguanidine and 108 g of Dimethyl amine hydrochloride were added to 400 g of n-butanol in a 1000 mL glass flask. The flask was equipped with cooling water condenser and the flask was allowed to reflux for 28 h. The resulting reaction mass was cooled to ambient temperature, preferably 10-110°C and filtered. Dried the obtained solid at 50°"75°C, to get Pure Metformin hydrochloride (188 g)
EXAMPLE 3: Preparation of metformin hydrochloride (Formula 1)
1 Kg of 2-cyanoguanidine and 1.15 Kg of Dimethyl amine hydrochloride were added to 2 Kg of n-butanol in a 5 L glass flask. The flask was equipped with cooling water condenser and the flask was allowed to reflux for 22 h. The resulting reaction mass was cooled to ambient temperature, preferably 10-110°C and filtered. Dried the obtained solid at 50°"75°C, to get Pure Metformin hydrochloride (1.9 Kg)
Above obtained Metformin Hydrochloride samples were analyzed for related substances by HPLC as per the European Pharmacopoeia monograph (Ph. Eur) 8.0
Single Maximum Metformin
Total
Examples Unknown Hydrochloride
impurities
Impurity purity
1 0.02% 0,03% 99.97%
2 0,02% 0,05% 99.95%
3 0,01 % 0,04% 99.96%
Content of related impurity- A, Impurity -F and Melamine is as follows:
Examples Related compound A Impurity-F content Melamine content
1 0.01 % 2 ppm Not detected
2 0.01 % 3 ppm Not detected
3 0.01 % 2 ppm Not detected
Related compound- A is 2-cyanoguamdine
Impurity -F is Dimethylaniine
Claims
CLAIMS:
1) An improved process for the preparation of Metformin or its pharmaceutically acceptable salts, comprising the steps of
i) treating dimethyl amine in the form of salt with 2-cyanoguanidine (DCDA) in presence of minimum amount of alcoholic solvent.
ii) isolation of Metformin by filtration without washing with alocoholic solvent and drying to get compound of formula-I as a pure product or iii) Washing step (ii) with alcoholic solvent and drying to get compound of formula- 1 as a pure product.
2) The process according to claim 1, wherein pharmaceutically acceptable salts are organic or inorganic salts thereof.
3) The process according to claim 1, wherein alcoholic solvent selected from primary, secondary or tertiary alcohols, preferably primary alcohols, more preferably n-butanol.
4) The process according to claim 1, wherein the reaction temperature is selected from ambient to reflux temperature.
5) An improved process for the preparation of Metformin hydrochloride, comprising the steps of
i) treating dimethyl amine hydrochloride (DMA HC1) with 2-cyanoguanidine (DCDA) in presence of n-butanol
ii) isolation of Metformin hydrochloride by filtration without washing with alocoholic solvent and drying to get compound of formula-I as a pure product or
iii) washing wet compound from step (ii) with n-butanol and drying to get pure Metformin hydrochloride as a product.
6) The process according to claim 5, step (i) is carried out at ambient to reflux temperature and step (ii) or step (iii) is carried out at a temperature 10°C to 110°C.
7) The process according to claim 5, yield and purity of Metformin hydrochloride is not less than 92 % and not less than 99.5 % respectively.
8) The process according to claim 5, isolated Metformin hydrochloride contains dimethyl amine content less than 5ppm. 9) The process according to claim 5, the content of melamine and 2- cyanoguanidine (DCDA) is less than 0.02%, more preferably 0.01%.
10) The process according to claim 5, wherein process provides therapeutically effective amount of Metformin Hydrochloride substantially free from dimethyl amine and related impurities.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201580055452.2A CN106795104A (en) | 2014-10-13 | 2015-10-03 | The improved method for preparing high-purity melbine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5121/CHE/2014 | 2014-10-13 | ||
| IN5121CH2014 | 2014-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016059507A1 true WO2016059507A1 (en) | 2016-04-21 |
Family
ID=55746200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/057575 WO2016059507A1 (en) | 2014-10-13 | 2015-10-03 | Improved process for the preparation of high pure metformine |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106795104A (en) |
| WO (1) | WO2016059507A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778202A (en) * | 2016-08-30 | 2018-03-09 | 天津太平洋制药有限公司 | A kind of preparation method of Metformin hydrochloride |
| WO2021044445A1 (en) * | 2019-09-06 | 2021-03-11 | Council Of Scientific And Industrial Research | Solvent free continuous process for the synthesis of metformin hyrochloride |
| JP2021512886A (en) * | 2018-02-07 | 2021-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | How to make metformin |
| GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110256300B (en) * | 2019-06-26 | 2022-04-05 | 武汉大学 | Metformin hydrochloride compound and metformin hydrochloride tablet composition |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2448448A (en) | 1942-06-08 | 1948-08-31 | Courtaulds Ltd | Dyeing of textile fibers containing nitrogen |
| DE1023757B (en) | 1955-08-31 | 1958-02-06 | Ludwig Heumann & Co Chem Pharm | Process for the preparation of monosubstituted, aliphatic biguanide salts |
| FR1324295A (en) * | 1962-03-05 | 1963-04-19 | Prod De Chimie Organique De La | Process for the preparation of compounds of the biguanide series |
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| FR2322860A1 (en) | 1975-09-05 | 1977-04-01 | Aron Sarl | Dimethylbiguanide hydrochloride prepn. - by reaction of hydrogen chloride gas with a conc. soln. of dimethylamine and dicyandiamide in xylene |
| FR2696740A1 (en) * | 1992-10-13 | 1994-04-15 | Dospharma Sa | New di:methyl-biguanide imide derivs. - useful for treating diabetes and circulatory disorders |
| IN189077B (en) | 2001-03-08 | 2002-12-14 | Panchagnula Srinivasa Murthy | |
| CN1844093A (en) * | 2006-05-10 | 2006-10-11 | 翟树军 | Process for preparing metformin hydrochloride |
| CN101450920A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Method for producing metformin hydrochloride large particle crystal |
| CN101450919A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Metformin hydrochloride purification method |
| WO2010146604A2 (en) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Processes for preparing metformin hydrochloride |
| WO2014041566A2 (en) | 2012-09-17 | 2014-03-20 | Laurus Labs Private Limited | An improved process for the preparation of metformin hydrochloride |
-
2015
- 2015-10-03 CN CN201580055452.2A patent/CN106795104A/en active Pending
- 2015-10-03 WO PCT/IB2015/057575 patent/WO2016059507A1/en active Application Filing
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2448448A (en) | 1942-06-08 | 1948-08-31 | Courtaulds Ltd | Dyeing of textile fibers containing nitrogen |
| DE1023757B (en) | 1955-08-31 | 1958-02-06 | Ludwig Heumann & Co Chem Pharm | Process for the preparation of monosubstituted, aliphatic biguanide salts |
| FR1324295A (en) * | 1962-03-05 | 1963-04-19 | Prod De Chimie Organique De La | Process for the preparation of compounds of the biguanide series |
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| FR2322860A1 (en) | 1975-09-05 | 1977-04-01 | Aron Sarl | Dimethylbiguanide hydrochloride prepn. - by reaction of hydrogen chloride gas with a conc. soln. of dimethylamine and dicyandiamide in xylene |
| FR2696740A1 (en) * | 1992-10-13 | 1994-04-15 | Dospharma Sa | New di:methyl-biguanide imide derivs. - useful for treating diabetes and circulatory disorders |
| IN189077B (en) | 2001-03-08 | 2002-12-14 | Panchagnula Srinivasa Murthy | |
| CN1844093A (en) * | 2006-05-10 | 2006-10-11 | 翟树军 | Process for preparing metformin hydrochloride |
| CN100391939C (en) | 2006-05-10 | 2008-06-04 | 翟树军 | Process for preparing metformin hydrochloride |
| CN101450920A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Method for producing metformin hydrochloride large particle crystal |
| CN101450919A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Metformin hydrochloride purification method |
| WO2010146604A2 (en) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Processes for preparing metformin hydrochloride |
| US20110021634A1 (en) | 2009-06-18 | 2011-01-27 | Patel Pranav Dushyant | Processes for preparing metformin hydrochloride |
| WO2014041566A2 (en) | 2012-09-17 | 2014-03-20 | Laurus Labs Private Limited | An improved process for the preparation of metformin hydrochloride |
Non-Patent Citations (3)
| Title |
|---|
| J. CHEM, SOC., vol. 121, 1922, pages 1790 |
| NIKHIL SACHDEVA ET AL: "Regioselective synthesis of pyrimido[1,2-a][1,3,5]triazin-6-ones via reaction of 1-(6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethylorthoacetate: observation of an unexpected rearrangement", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 23, January 2012 (2012-01-01), GB, pages 4586, XP055226481, ISSN: 1477-0520, DOI: 10.1039/c2ob25195g * |
| PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 21, no. 12, 1987, pages 892 - 894 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778202A (en) * | 2016-08-30 | 2018-03-09 | 天津太平洋制药有限公司 | A kind of preparation method of Metformin hydrochloride |
| JP2021512886A (en) * | 2018-02-07 | 2021-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | How to make metformin |
| JP7447005B2 (en) | 2018-02-07 | 2024-03-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for manufacturing metformin |
| WO2021044445A1 (en) * | 2019-09-06 | 2021-03-11 | Council Of Scientific And Industrial Research | Solvent free continuous process for the synthesis of metformin hyrochloride |
| GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2023156645A1 (en) | 2022-02-21 | 2023-08-24 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106795104A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016059507A1 (en) | Improved process for the preparation of high pure metformine | |
| RU2669388C1 (en) | N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide monohydrate | |
| US9216943B2 (en) | Preparation of fingolimod and its salts | |
| WO2011161690A1 (en) | Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof | |
| CA2561987A1 (en) | Process for the preparation of highly pure hydroxychloroquine or a salt thereof | |
| US8236991B2 (en) | Process for the preparation of substantially pure (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane | |
| US7777037B2 (en) | Ziprasidone process | |
| KR20010043392A (en) | Improvements in Macrolide Production | |
| CZ20023903A3 (en) | Novel amorphous form of sertraline hydrochloride | |
| US20160355533A1 (en) | Crystalline Fosaprepitant Dicyclohexylamine Salt And Its Preparation | |
| US20160304520A1 (en) | An improved process for preparing Linagliptin and its key Intermediates | |
| CN114040906A (en) | Novel preparation method of peramivir trihydrate and water system drying method thereof | |
| US9346743B2 (en) | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds | |
| KR20060041207A (en) | Process for iohexol manufacture | |
| WO2011158249A1 (en) | Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran | |
| US8598370B2 (en) | Process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine | |
| US20220098216A1 (en) | Process for the preparation of midostaurin with high purity | |
| US10815204B2 (en) | Process for the preparation of diphenylpyrazine derivatives | |
| US10300044B2 (en) | Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof | |
| EA029788B1 (en) | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine | |
| US10961194B2 (en) | Method for purifying ropinirole hydrochloride | |
| US20210188767A1 (en) | Method for the purification of cysteamine | |
| CN112521380A (en) | Synthetic method of rivaroxaban intermediate A and application of rivaroxaban intermediate A in preparation of rivaroxaban | |
| US10428033B2 (en) | Process for the preparation of vortioxetine and salts thereof | |
| US20070066824A1 (en) | Preparation of alfuzosin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15778055 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15778055 Country of ref document: EP Kind code of ref document: A1 |